Literature DB >> 4005876

Antitumor activity of a benzaldehyde derivative.

M Kochi, N Isono, M Niwayama, K Shirakabe.   

Abstract

Benzaldehyde, in the form of 4,6-benzylidene-alpha-D-glucose (BG), was given iv at a daily dose of 720-1800 mg/m2 to 65 patients with inoperable carcinoma in the advanced stages. The overall objective response rate was 55%; seven patients achieved complete response, 29 achieved partial response, 24 remained stable, and five showed progressive disease. Response was seen in various cell types. Prolongation of survival was apparent for the patients. Toxic reactions were not observed during long-term injection with BG.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4005876

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  7 in total

1.  In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats.

Authors:  J M Dornish; R O Larsen; P E Schwarze; B Børretzen; E O Pettersen
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.

Authors:  C B Dunsaed; J M Dornish; E O Pettersen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  4, 6-0-benzylidene-D-glucopyranose (BG) in the treatment of solid malignant tumours, an extended phase I study.

Authors:  T Tatsumura; M Tsujimoto; S Koyama; T Furuno; Y Komori; H Sato; K Yamamoto; M Kitagawa; S Kagamimori
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

4.  Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells.

Authors:  Naomi Sugimori; J Luis Espinoza; Ly Quoc Trung; Akiyoshi Takami; Yukio Kondo; Dao Thi An; Motoko Sasaki; Tomohiko Wakayama; Shinji Nakao
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

5.  Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease.

Authors:  Vasundara Srinivasan; Hévila Brognaro; Prince R Prabhu; Edmarcia Elisa de Souza; Sebastian Günther; Patrick Y A Reinke; Thomas J Lane; Helen Ginn; Huijong Han; Wiebke Ewert; Janina Sprenger; Faisal H M Koua; Sven Falke; Nadine Werner; Hina Andaleeb; Najeeb Ullah; Bruno Alves Franca; Mengying Wang; Angélica Luana C Barra; Markus Perbandt; Martin Schwinzer; Christina Schmidt; Lea Brings; Kristina Lorenzen; Robin Schubert; Rafael Rahal Guaragna Machado; Erika Donizette Candido; Danielle Bruna Leal Oliveira; Edison Luiz Durigon; Stephan Niebling; Angelica Struve Garcia; Oleksandr Yefanov; Julia Lieske; Luca Gelisio; Martin Domaracky; Philipp Middendorf; Michael Groessler; Fabian Trost; Marina Galchenkova; Aida Rahmani Mashhour; Sofiane Saouane; Johanna Hakanpää; Markus Wolf; Maria Garcia Alai; Dusan Turk; Arwen R Pearson; Henry N Chapman; Winfried Hinrichs; Carsten Wrenger; Alke Meents; Christian Betzel
Journal:  Commun Biol       Date:  2022-08-11

Review 6.  Laetrile treatment for cancer.

Authors:  Stefania Milazzo; Markus Horneber
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

7.  Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H).

Authors:  E O Pettersen; R O Larsen; J M Dornish; B Børretzen; M E Juul; T E Aastveit; J M Nesland; E K Rofstad; R Oftebro
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.